3.285
price down icon1.05%   -0.035
 
loading
전일 마감가:
$3.32
열려 있는:
$3.3
하루 거래량:
185.96K
Relative Volume:
0.07
시가총액:
$158.93M
수익:
-
순이익/손실:
$-97.22M
주가수익비율:
-2.3804
EPS:
-1.38
순현금흐름:
$-82.44M
1주 성능:
+1.08%
1개월 성능:
+7.70%
6개월 성능:
+54.95%
1년 성능:
+7.35%
1일 변동 폭
Value
$3.2588
$3.38
1주일 범위
Value
$2.88
$3.38
52주 변동 폭
Value
$1.15
$4.98

카사바 Stock (SAVA) Company Profile

Name
명칭
Cassava Sciences Inc
Name
전화
512-501-2444
Name
주소
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Name
직원
30
Name
트위터
Name
다음 수익 날짜
2025-08-08
Name
최신 SEC 제출 서류
Name
SAVA's Discussions on Twitter

SAVA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SAVA
Cassava Sciences Inc
3.2899 160.38M 0 -97.22M -82.44M -1.38
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.30 116.04B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
729.12 75.97B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
461.29 61.48B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
905.88 56.40B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
205.23 43.73B 447.02M -1.18B -906.14M -6.1812

카사바 Stock (SAVA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-26 다운그레이드 H.C. Wainwright Buy → Neutral
2024-10-08 업그레이드 H.C. Wainwright Neutral → Buy
2024-07-01 다운그레이드 H.C. Wainwright Buy → Neutral
2022-11-16 다운그레이드 B. Riley Securities Buy → Neutral
2021-07-15 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2021-07-07 재확인 Maxim Group Buy
2021-04-27 개시 B. Riley Securities Buy
2021-02-16 재확인 H.C. Wainwright Buy
2020-10-23 개시 Cantor Fitzgerald Overweight
2020-09-23 업그레이드 H.C. Wainwright Neutral → Buy
2020-05-18 다운그레이드 H.C. Wainwright Buy → Neutral
2020-05-15 다운그레이드 Maxim Group Buy → Hold
2020-01-10 재확인 Maxim Group Buy
모두보기

카사바 주식(SAVA)의 최신 뉴스

pulisher
07:18 AM

Why Cassava Sciences Inc. Equity Warrant stock is rated strong buyDividend Hike & High Accuracy Investment Signals - Newser

07:18 AM
pulisher
04:48 AM

Why Cassava Sciences Inc. (PX91) stock appeals to dividend investors2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - Newser

04:48 AM
pulisher
03:39 AM

Why Cassava Sciences Inc. (PX91) stock could be next leader2025 Market Trends & Weekly Consistent Profit Watchlists - Newser

03:39 AM
pulisher
Dec 04, 2025

Can Cassava Sciences Inc. (PX91) stock deliver double digit returnsJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

What analysts say about Cassava Sciences Inc Equity Warrant stock - earlytimes.in

Dec 04, 2025
pulisher
Dec 04, 2025

How Cassava Sciences Inc. Equity Warrant stock compares to industry benchmarksPortfolio Value Summary & AI Forecasted Entry and Exit Points - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

How Cassava Sciences Inc. (PX91) stock trades after rate cuts2025 Performance Recap & AI Powered Buy/Sell Recommendations - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

Cassava Sciences IncFDA requires additional information from Cassava for clinical studySEC filing - marketscreener.com

Dec 03, 2025
pulisher
Dec 03, 2025

Cassava Says US FDA Seeks Additional Information for Simufilam IND Application for TSC-Related Epilepsy - MarketScreener

Dec 03, 2025
pulisher
Dec 03, 2025

Cassava Sciences hit with FDA request for more data on simufilam trial (SAVA:NASDAQ) - Seeking Alpha

Dec 03, 2025
pulisher
Dec 03, 2025

Cassava Sciences receives FDA request for more information on epilepsy trial - Investing.com

Dec 03, 2025
pulisher
Dec 03, 2025

Cassava Sciences Submits IND Application for Simufilam - TipRanks

Dec 03, 2025
pulisher
Dec 03, 2025

Cassava Sciences stock falls after FDA requests more data for epilepsy drug - Investing.com Canada

Dec 03, 2025
pulisher
Dec 03, 2025

Does Cassava Sciences Inc. stock trade at a discount to peersAnalyst Downgrade & Weekly High Return Stock Forecasts - Newser

Dec 03, 2025
pulisher
Dec 03, 2025

Cassava Sciences Receives FDA Request for Additional Information - TradingView

Dec 03, 2025
pulisher
Dec 03, 2025

Will Cassava Sciences Inc. (PX91) stock beat Nasdaq index returnsJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

Is Cassava Sciences Inc. stock a buy for dividend growthJuly 2025 Market Mood & Low Risk Investment Opportunities - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Published on: 2025-12-02 02:52:36 - Newser

Dec 02, 2025
pulisher
Nov 27, 2025

How Cassava Sciences Inc. stock responds to policy changesJuly 2025 Patterns & Growth Oriented Trade Recommendations - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 27, 2025

Can Cassava Sciences Inc. stock outperform in 2025 bull marketWeekly Trade Report & Free Weekly Watchlist of Top Performers - moha.gov.vn

Nov 27, 2025
pulisher
Nov 26, 2025

Aug Sectors: What valuation multiples suggest for Cassava Sciences Inc. Equity Warrant stockDollar Strength & Real-Time Sentiment Analysis - BỘ NỘI VỤ

Nov 26, 2025
pulisher
Nov 25, 2025

Dir Anderson Jr Buys 8,600 ($24.9K) Of Cassava Sciences Inc [SAVA] - TradingView

Nov 25, 2025
pulisher
Nov 25, 2025

[Form 4] CASSAVA SCIENCES INC Insider Trading Activity - Stock Titan

Nov 25, 2025
pulisher
Nov 24, 2025

Cassava Sciences rises 10% after market close on CEO stock buy - MSN

Nov 24, 2025
pulisher
Nov 23, 2025

February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Cla - GuruFocus

Nov 23, 2025
pulisher
Nov 22, 2025

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - MSN

Nov 22, 2025
pulisher
Nov 21, 2025

Cassava Sciences (NASDAQ:SAVA) CEO Purchases $201,808.75 in Stock - MarketBeat

Nov 21, 2025
pulisher
Nov 21, 2025

Should You Invest in Dishman Carbogen Amcis Limited Before Its Next Earnings ReportEvening Star Patterns & Rapid Capital Portfolio - earlytimes.in

Nov 21, 2025
pulisher
Nov 21, 2025

Cassava Sciences Sees Unusually High Options Volume (NASDAQ:SAVA) - MarketBeat

Nov 21, 2025
pulisher
Nov 21, 2025

Cassava Sciences Stock Rise as CEO Makes Insider Purchase - Somos Hermanos -

Nov 21, 2025
pulisher
Nov 21, 2025

Is Cassava Sciences Inc. stock attractive for retirement portfoliosGap Up & Safe Capital Allocation Plans - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Cassava Sciences stock up as CEO buys shares (SAVA:NASDAQ) - Seeking Alpha

Nov 21, 2025
pulisher
Nov 21, 2025

Is Cassava Sciences Inc. stock attractive for income investorsMarket Trend Report & AI Enhanced Trading Signals - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Is Cassava Sciences Inc. stock a defensive play in 2025Market Performance Report & AI Powered Market Entry Strategies - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Why global investors buy Cassava Sciences Inc. (PX91) stockPortfolio Value Summary & Low Risk High Reward Trade Ideas - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Why Cassava Sciences Inc. Equity Warrant stock could be next big winnerPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Can Cassava Sciences Inc. stock deliver consistent earnings growth2025 Volatility Report & Fast Entry High Yield Tips - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Why Cassava Sciences Inc. Equity Warrant stock is favored by top institutions2025 Key Highlights & Capital Protection Trading Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What momentum indicators show for Cassava Sciences Inc. stockGold Moves & Real-Time Chart Breakout Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will Cassava Sciences Inc. Equity Warrant stock deliver shareholder value - newser.com

Nov 19, 2025

카사바 (SAVA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

카사바 주식 (SAVA) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Barry Richard
President & CEO
Nov 20 '25
Buy
2.76
150,000
414,000
938,060
Barry Richard
President & CEO
Nov 19 '25
Buy
2.75
73,385
201,809
788,060
Cook Robert Christopher
Chief Operating & Legal Office
Sep 30 '25
Buy
2.91
13,725
39,940
13,725
Barry Richard
President & CEO
Sep 22 '25
Buy
2.28
7,172
16,352
714,675
Barry Richard
President & CEO
Sep 18 '25
Buy
2.24
190,633
426,424
660,195
Barry Richard
President & CEO
Sep 19 '25
Buy
2.29
47,308
108,319
707,503
$39.13
price up icon 0.14%
$31.89
price down icon 0.34%
$100.21
price down icon 0.18%
$96.34
price up icon 0.67%
biotechnology ONC
$319.06
price down icon 3.69%
$205.53
price up icon 0.26%
자본화:     |  볼륨(24시간):